From the boardroom to the consulting room: pharma’s role in curing gender bias

pharma

(Louis Reed, Unsplash)

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Jayasree K. Iyer, Executive Director, Access to Medicine Foundation


• Pharma companies putting greater priority on women makes sense financially and in terms of healthcare impact.

• Women in low-income countries bear a disproportionate disease burden.

• More women in the boardroom should affect drug development and delivery strategies on the ground.

Pharmaceutical companies have a chance to make the world a healthier place by curing gender bias. Empowering women in decisions about drug research and access to medicines can pave the way to truly equitable healthcare.

The business case for promoting gender equity is now widely accepted. Indeed, diversity has been a focus for companies and investors alike for nearly a decade, with the UK’s 30% Club launched in 2010, and France having gender quotas for boards since 2011. Investment firms are also watching intently, with Morgan Stanley recently launching a scorecard to assess gender balance within workforces. In healthcare, the World Health Organization now uses a gender responsiveness scale for assessing health programmes.

So how can pharmaceutical companies do a better job of rebalancing their working practices and eradicating gender biases in the way they bring healthcare to the world? To begin with, CEOs and investors need to understand what it means to make gender equity a pillar of strategy – and appreciate how this will benefit them both financially and increase their healthcare impact.

Healthy leadership

Let’s start with women in leadership. Only a few of the biggest pharmaceutical companies – such as GSK, Mylan, Biocon and Biological E – currently have a female CEO, and women make up under 30% of executive directors at the top firms. This is despite the fact that similar numbers of men and women enter the workforce with advanced degrees in life sciences and medicine. While a few companies, like Johnson & Johnson and Pfizer, have women in about 40% of executive committee roles, many more have only negligible female representation. Women at Bayer, for example, make up under 10% of the senior executive team. For better decision-making, gender equity is needed across the company, including country-level teams.

Women make up under 30% of executive directors at top pharma firms
Women make up under 30% of executive directors at top pharma firms

The financial argument for gender equity is strong. Companies in the UK’s FTSE 350 index with no women on their executive committee achieved an average 8.9% net profit margin, while those with at least 25% women executives averaged 13.9%, according to a 2018 report.

Respective profits of FTSE companies with different proportions of women executives
Respective profits of FTSE companies with different proportions of women executives

R&D with gender balance

There are specific reasons why gender matters in pharmaceuticals – starting with R&D. If drug companies are to fulfil their contract with society, they must tackle the most deadly diseases of the world, equitably. But in low-income countries, women and girls bear a bigger burden of disease than men. Some diseases only or disproportionately affect women, such as gynaecological conditions, breast cancer or sexually transmitted infections (STIs). So paying attention to diversity means ensuring that R&D serves both genders equally.

Proportion of women in low-income countries
Proportion of women in low-income countries

In some areas, industry is making important contributions. New contraceptives designed for low-income countries have been prioritized by the likes of Bayer, Merck & Co and Pfizer, while heat-stable carbetocin for post-partum haemorrhage (the leading cause of maternal deaths) has been developed by Ferring Pharma and Merck for Mothers. Two drugs against resistant forms of gonorrhea are also being developed by GSK and biotech firm Entasis. Yet there are still many gaps. A new treatment for endometriosis is desperately needed, as are better drugs for STIs. The message is clear: More companies must get involved and stay committed if we are to eradicate gender as a social determinant of health.

Appropriate female enrolment in clinical trials is also critical. This may be obvious in a disease like breast cancer, but other conditions such as osteoarthritis also disproportionately affect women, and studies need to reflect this by including adequate female numbers.

The US Food and Drug Administration has highlighted the need for better gender balance in trials since 1992, following official reports noting a lack of female representation in federally funded studies of diseases including HIV/AIDS and hypertension. More recently, there has been a push to boost inclusion of cis and transgender individuals. Yet problems persist. In October 2019, a product for pre-exposure prophylaxis (PrEP) of HIV/AIDS was not granted FDA approval for expanded use in cisgender women due to lack of data, while it was approved for men and transgender women, where data was available.

Delivering healthcare to women and girls

Gender is also important when it comes to the way companies deliver products, since women and girls all too often fail to access effective and timely treatment in low-income countries. Even as we celebrate progress in the global response to HIV/AIDS, girls and young women in sub-Saharan Africa, who account for 71% of new HIV infections, are getting left behind. Companies can help with targeted programmes like the DREAMS partnership for adolescent girls with HIV, backed by the likes of Gilead, Johnson & Johnson and ViiV.

Similarly, the Mothers2Mothers initiative, supported by Johnson & Johnson and others, employs women living with HIV/AIDS as community health workers, calling them “Mentor Mothers”, tackling gender inequities in employment in health. And the HALOW scheme, backed by GSK, Marks & Spencer and CARE International, tackles healthcare inequities among workers in the garment industry – mostly impoverished women from rural areas who live in slums and lack access to health services due to their income and gender.

What’s the World Economic Forum doing about the gender gap?

The World Economic Forum has been measuring gender gaps since 2006 in the annual Global Gender Gap Report.

The Global Gender Gap Report tracks progress towards closing gender gaps on a national level. To turn these insights into concrete action and national progress, we have developed the Closing the Gender Gap Accelerators model for public private collaboration.

These accelerators have been convened in Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Panama and Peru in partnership with the InterAmerican Development Bank.

In 2019 Egypt became the first country in the Middle East and Africa to launch a Closing the Gender Gap Accelerator. While more women than men are now enrolled in university, women represent only a little over a third of professional and technical workers in Egypt. Women who are in the workforce are also less likely to be paid the same as their male colleagues for equivalent work or to reach senior management roles.

France has become the first G20 country to launch a Gender Gap Accelerator, signalling that developed economies are also playing an important role in spearheading this approach to closing the gender gap.

In these countries CEOs and ministers are working together in a three-year time frame on policies that help to further close the economic gender gaps in their countries. This includes extended parental leave, subsidized childcare and removing unconscious bias in recruitment, retention and promotion practices.

If you are a business in one of the Closing the Gender Gap Accelerator countries you can join the local membership base.

If you are a business or government in a country where we currently do not have a Closing the Gender Gap Accelerator you can reach out to us to explore opportunities for setting one up.

In the third decade of the 21st century, as we strive to meet the UN Sustainable Development Goals, it is unacceptable that problems of access to medicines should be multiplied by gender inequity – and the ability to reach the vulnerable, leaving no one behind, is a key predictor of how companies perform on access to healthcare.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Tackling obesity would boost economic and social well-being

Sudan: UN rights chief alarmed over ‘excessive force’, alleged use of live fire against protestors

What are the real debates surrounding immigration in an increasingly globalized world?

FROM THE FIELD: New sensors protect vulnerable Malawians against deadly lightning

Change is happening – and young people are leading the way forward

Greek citizens to pay the price again but Tsipras risks losing next elections

It’s time to ‘eliminate the scourge of conflict-related sexual violence’, urges UN chief

Violence will not deter Somali people in their pursuit of peace, says UN chief, in wake of lethal attacks

From sun-powered trikes to mind-controlled TV – 10 top gadgets unveiled at CES 2020

Third Facebook-Cambridge Analytica hearing: data breach prevention and cures

This electric plane has flown successfully for 30 minutes – is this the future of flying?

EU approves disbursement of €500 million in Macro-Financial Assistance to Ukraine

A Wholesome Health Care for Transgenders: Sex Reassignment Surgery

Germany: A grand coalition may trouble employers and bankers

Bank resolutions and recapitalisations by the ESM may end up politically swayed

There’s no vaccine for the infodemic – so how can we combat the virus of misinformation?

Cameroon: Clear ‘window of opportunity’ to solve crises rooted in violence – Bachelet

Water supply a human right but Greeks to lose their functioning utilities

Coronavirus: here’s what you need to know about face masks

An economist explains how to go carbon neutral in our lifetime

Coronavirus: Pandemic alert should be trigger for countries to do more against COVID-19

We need a fresh approach to climate change migration. This is why

As Houthi forces withdraw from key Yemeni ports, UN monitoring chief welcomes ‘first practical step on the ground’

Commission refers Denmark to the Court for failing to fulfil its obligations in relation to the name “Feta”

EU, Brazil to hold high level Summit in Brasilia

Summertime Consultation: 84% want Europe to stop changing the clock

In Rome you can swap plastic bottles for metro tickets

MWC 2016 LIVE: T-Mobile US reveals 5G trial plans

Localized microfactories – the new face of globalized manufacturing

GSMA Mobile 360: Connecting Cities, Connecting Lives, Connecting Europe

Protecting workers from biological agents: how to classify SARS-CoV-2

Nauru President warns of possible climate change ‘economic Armageddon’

“Private” sea freight indexes hide Libor like skeletons?

Time to be welcome: Youth work and integration of young refugees

Migrant workers sent more money to India than any other country last year

How the diaspora is helping Venezuela’s migration crisis

Gender inequality in the medicine field: two commonly issues

Meet Alice, the battery-powered plane that could herald the age of electric air travel

European Banking Union: no one is perfect

This graphene battery can recharge itself to provide unlimited clean energy

UN ‘stands in solidarity’ with cyclone-hit India – Secretary-General Guterres

Commission’s action plan: financial world mandatory links to environmental targets

Children are forgetting the names for plants and animals

What are plastics and why do they matter? An explainer

Turkey caught in a vicious Syrian circle bringing terror and war at home

Trump’s MAGA policy remains unchanged as EU warns to impose additional retaliation tariffs on US products

The first new university in the UK for 40 years is taking a very different approach to education

COVID-19: Single market must emerge stronger from the crisis, say MEPs

The Commission offers exit from the EU budget stalemate

Why banks escape from competition rules but not pharmaceutical firms

Korea should improve the quality of employment for older workers

Air pollution: How to end the deaths of 7 million people per year?

There is no patient safety without healthcare workers’ safety

The community and a decent working conditions for the young health workforce

Here’s what a Korean boy band can teach us about globalization 4.0

From a refugee camp to Davos: one Co-Chair’s story

‘Grave consequences’ await if new deadly escalation of violence in Gaza continues – top UN official

Asian and Pacific economies: decreases in tax revenue highlight need to broaden tax bases

Scotland in United Kingdom: It’s either the end or the beginning of the end

A young student discusses the determinants of migration in the European Union

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s